BOSTON – Nov. 15, 2022 – David J. Dykeman, co-chair of global law firm Greenberg Traurig, LLP’s global Life Sciences & Medical Technology Practice and co-managing shareholder of the firm’s Boston office, spoke on a panel titled “Ownership and Inventorship 2.0: Common and Contemporary IP Due Diligence Landmines for the Life Sciences,” Nov. 15 at the American Conference Institute (ACI) 5th Annual Summit on Life Sciences Intellectual Property (IP) Due Diligence.
The panel discussed the implications for life sciences companies employing artificial intelligence (AI) technologies, unique due diligence strategies for life sciences IP assets involving AI, how to determine inventorship and ownership with multiple inventors, assessing the risk of litigation, analyzing the target company’s policies, and who owns data.
A registered patent attorney with 25 years of experience in patent and IP law, Dykeman focuses his practice on securing worldwide IP protection and related business strategy for high tech clients, with particular experience in life sciences, medical devices, robotics, materials, and information technology. Dykeman provides strategic patent portfolio development and IP advice for clients, including major research institutions, multinational corporations, and early-stage companies. He also performs patent due diligence to assess patent portfolios for venture capital investment, mergers and acquisitions, and licensing opportunities. An author of over 55 articles and a speaker at over 50 conferences on IP law, Dykeman is the founding co-chair of the American Bar Association’s Medical Devices Committee. In 2022, Dykeman was named “Patent Strategy Attorney of the Year for Massachusetts” by LMG Life Sciences.